Latest News
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
In recognition of Macular Degeneration Awareness Month this February, BrightFocus Foundation, a nonprofit dedicated to ending diseases of mind and sight, is offering a variety of free educational resources to help individuals with macular degeneration and their loved ones navigate the disease.
The U.S. Food and Drug Administration in November granted Breakthrough Therapy designation for a new treatment that could slow the progression of geographic atrophy, an advanced and severe form of dry age-related macular degeneration that can lead to permanent vision loss.
David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.
If approved, the drug pegcetacoplan would become the first-ever treatment in the U.S. for geographic atrophy, a blinding and advanced form of age-related macular degeneration.
In this issue:
- President’s Corner
- One-Time Gene Therapy for Wet AMD
- DNA Modifcation and Gene Expression in AMD
- And more!
A team including two BrightFocus grantees has successfully transplanted a patch of retinal tissue into a patient with geographic atrophy. This experimental therapy was part of an NIH clinical trial and marks the first time in the U.S. that stem cells derived from a patient’s own tissue have been used to replace eye cells.
A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.
In this issue:
- President's Corner
- Parallels Found Between AMD Changes and Liver Cells
- How a High-Fat Diet Influences AMD
- And more!
In this issue:
- Researchers Discover Mechanisms Underlying Drusen Formation
- President's Corner
- Targeting Drusen Production in the Retina
- FDA Approves New Treatment for Macular Degeneration
- And more!
